Opus Genetics Presents Phentolamine Ophthalmic Solution 0.75% Improves Visual Acuity in Patients with Dim Light Disturbances, World Cornea Congress IX

Opus Genetics, Inc. shared the positive findings of their Phentolamine Ophthalmic Solution 0.75% to improve visual acuity in patients with dim light disturbances last week at the World Cornea Congress IX in Washington D.C. The results are from the company’s LYNX-1 phase 3 clinical trial.

Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. It is currently being investigated in phase 3 trials for treatment of presbyopia and reduced dim (mesopic) light low contrast vision following keratorefractive surgery. 

Jay Pepose, MD, PhD, and Chief Medical Advisor at Opus Genetics presented the study findings at a Paper session on Friday, March 21. Key highlights from his presentation include:

• A statistically significant greater percentage of patients treated with Phentolamine Ophthalmic Solution 0.75% gained 15 or more letters of mesopic low contrast distance visual acuity (mLCVA) at Day 8, compared to placebo (13% vs. 3%; p<0.05).
• The effect of Phentolamine Ophthalmic Solution 0.75% increased at Day 15, with 21% of participants gaining 15 or more letters of mLCVA compared to 3% of participants given the placebo (p<0.01).
• Patients treated Phentolamine Ophthalmic Solution 0.75% reported significantly fewer glare, halos, and starbursts compared to placebo at Day 15 (p<0.01).
• The effect of Phentolamine Ophthalmic Solution 0.75% was sustained at Day 15 in post-LASIK participants, with 21% of participants gaining 15 or more letters of mLCVA compared to 0% of participants given the placebo.

“We are pleased to present the results from the LYNX-1 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75%, including a subset analysis highlighting results from participants who underwent some form of keratorefractive surgery, including LASIK,” Dr. Pepose said. “Some patients who underwent keratorefractive surgery have experienced debilitating reduced mesopic vision and are more likely to be involved in motor vehicle collisions. Phentolamine Ophthalmic Solution 0.75% has the potential to be the first treatment for keratorefractive patients suffering from these debilitating symptoms.”

The fully study abstract is available at the World Cornea Congress IX website here. The company has a second study investigating Phentolamine Ophthalmic Solution 0.75% for keratorefractive patients with reduced mLCVA with photic phenomena. LYNX-2 is fully enrolled, with results expected later this year.